Clinical trials in Potsdam – page 10

1 819 clinical trials in Potsdam, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Potsdam at a glance

1 819

clinical trials

Research sites1

Quick filters

1 819 trials in Potsdam

Open in trial search

Type 2 diabetes mellitus

Recruiting

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Interstitial lung disease

Recruiting

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Nerandomilast
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Parkinson's disease

Recruiting

A Phase II Randomized, Double‑Blind Study of RO7568282 for Safety and Efficacy in Early‑Stage Parkinson’s Disease Patients

Investigational

A Phase II Randomized, Double‑Blind Study of RO7568282 for Safety and Efficacy in Early‑Stage Parkinson’s Disease Patients

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Siltuximab
Sponsor:Amgen Inc.

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Phase 1 Study of JNJ-95804306 in Adults with Relapsed or Refractory AML, Higher‑Risk MDS, CLL and SLL

InvestigationalNo placebo

Phase 1 Study of JNJ-95804306 in Adults with Relapsed or Refractory AML, Higher‑Risk MDS, CLL and SLL

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Janssen Cilag International

Contact Research Centre

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bosutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epoetin Alfa
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Congenital myopathy

Recruiting

A study to evaluate the safety and effectiveness of surlorian in adults with RYR1-related myopathy

Investigational

A study to evaluate the safety and effectiveness of surlorian in adults with RYR1-related myopathy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Surlorian
Sponsor:Armgo Pharma Inc.

Contact Research Centre

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Potsdam

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative, HER2-positive, and hormone receptor-positive variants. Research encompasses new combination therapies and targeted treatments.

Early-stage breast cancer interventions
HPV-positive oropharyngeal cancer treatments
Advanced treatment strategies

Multiple studies are evaluating novel drug combinations and personalized therapeutic approaches.

02 Dermatological Studies

Clinical research targeting various skin conditions, including atopic dermatitis and chronic skin disorders. Studies focus on both topical and systemic treatments.

Actinic keratosis treatments
Hidradenitis suppurativa therapy
Plaque psoriasis management

Investigations include both traditional and innovative therapeutic approaches for skin conditions.

03 Neurological Research

Studies focusing on multiple sclerosis treatment options, evaluating new medications and comparing their effectiveness to existing therapies.

Relapsing-remitting MS treatments
Novel therapeutic approaches
Disease modification strategies

Research aims to improve treatment outcomes and quality of life for patients with neurological conditions.

04 Cardiovascular Studies

Research focusing on cardiovascular disease management and innovative treatments for related conditions, including studies on lipid management.

Lipoprotein management
Cholesterol reduction therapies
Cardiovascular risk prevention

Trials aim to reduce major cardiovascular events and improve patient outcomes.

Back to Germany All countries